Ayati Devices: The Startup Making Diabetes Detection Fast and Portable
Backed by clinical validation and global reach, Ayati Devices is simplifying diabetic foot screening through cutting-edge MedTech.


In a country where diabetes affects over 77 million individuals, early detection of diabetic complications is paramount. Ayati Devices, a Bengaluru-based MedTech startup founded in 2019 by Nishant Kathpal, is making significant strides in this arena by developing portable, affordable diagnostic tools aimed at early neuropathy detection.
Addressing a Critical Healthcare Challenge
Diabetic Peripheral Neuropathy (DPN) is a common yet often overlooked complication of diabetes, leading to numbness, pain, and, in severe cases, foot ulcers and amputations. Traditional diagnostic methods are often expensive, time-consuming, and inaccessible to many, especially in rural areas. Ayati Devices seeks to bridge this gap by offering innovative solutions that are both effective and accessible.
Innovative Product Lineup
Ayati Devices has developed a suite of products designed to facilitate early detection and management of neuropathy:
- Vibrasense: A compact, battery-powered device that quantifies vibration perception threshold (VPT), aiding in the early detection of neuropathy. Its portability makes it ideal for use in outpatient departments, home visits, and screening camps.
- Vibrasense + T: An advanced version that simplifies Quantitative Sensory Testing, providing accurate results effortlessly.
- Neurosense Kit: A comprehensive toolkit that includes devices like Vibrasense Mini, Fibrasense, Thermasense, and Reflexsense, offering a full spectrum of neuropathy assessments.
- Podiasense Kit: Designed for thorough diabetic foot screening, this kit combines multiple tools to assess various risk factors associated with diabetic foot complications.
These devices are not only user-friendly but also integrate seamlessly with digital platforms, allowing for efficient data collection and analysis.
Impact and Recognition
Since its inception, Ayati Devices has made significant inroads:
- Global Reach: Over 5,500 devices deployed across 17 countries, impacting more than one million lives.
- Clinical Validation: All products are clinically validated and comply with international regulatory standards, including ISO 13485 certification.
- Awards and Accolades: The company has garnered over 20 awards, including the Best Startup Award in the healthcare category at the Indian IoT Congress and recognition in the Qualcomm Design in India Challenge.
- Shark Tank India: Ayati Devices gained national attention by securing ₹1 crore in funding on Shark Tank India Season 4, highlighting investor confidence in their mission and technology.
Vision for the Future
Ayati Devices envisions becoming a global leader in providing first-level, innovative, and affordable healthcare monitoring solutions. With plans to expand into markets across the Middle East and Africa, the company aims to make early neuropathy detection accessible to all, regardless of geographic or economic barriers.
Conclusion
Ayati Devices exemplifies how innovation and empathy can converge to address pressing healthcare challenges. By focusing on early detection and affordable diagnostics, they are not only improving patient outcomes but also setting new standards in preventive healthcare. As diabetes continues to pose significant health risks globally, solutions like those offered by Ayati Devices are crucial in mitigating complications and enhancing quality of life.